Agilent Q4 Revenues Inch up 2 Percent; Dako Drives Dx Growth | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market on Monday that revenues for its Fiscal Year 2012 fourth quarter increased 2 percent year over year.

Total revenues for the three months ended Oct. 31 rose to $1.77 billion from $1.73 billion a year ago, edging out the average analyst estimate of $1.76 billion. Orders during the quarter were flat at $1.75 million.

"The headline for this quarter is that most of our end markets remained soft," Agilent CEO Bill Sullivan said on a conference call after the release of the company's earnings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.